• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Abliva

Less than 1K followers
All
Webcasts
Press releases
3rd party
ShowingAll content types

Press release17.03.2025 klo 13.05

BioStock: Last trading day for Abliva - the company leaves Nasdaq Stockholm

Abliva
Regulatory press release03.03.2025 klo 14.10

Delisting of the shares of Abliva: last day of trading 17 March 2025

Abliva
Regulatory press release26.02.2025 klo 09.30

Notice of Extraordinary General Meeting in Abliva AB (publ)

Abliva

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release25.02.2025 klo 10.50

Abliva applies for delisting and will convene an extraordinary general meeting

Abliva
Regulatory press release21.02.2025 klo 09.30

Abliva AB Year-End Report January – December 2024

Abliva
Press release10.02.2025 klo 11.43

BioStock: Pharming completes bid for Abliva

Abliva
Regulatory press release15.12.2024 klo 21.00

Statement by the Board of Directors of Abliva regarding the public cash offer from Pharming

Abliva
Press release09.12.2024 klo 09.32

Abliva Announces Publication of Results from Phase 1a/b Study of KL1333 in the Scientific Journal Brain

Abliva
Press release04.12.2024 klo 12.34

BioStock: From mutation to solution - Abliva gains ground

Abliva
Regulatory press release29.11.2024 klo 19.00

Abliva AB Interim Report January – September 2024

Abliva
Press release04.11.2024 klo 12.00

Abliva will present at the BioStock Life Science Summit, November 21

Abliva
Press release18.09.2024 klo 10.38

BioStock: Abliva leads the fight against mitochondrial disease

Abliva
Press release16.09.2024 klo 09.30

Join Abliva for World Mitochondrial Disease Week 2024, September 16 – 22

Abliva
Regulatory press release30.08.2024 klo 09.30

Amended number of shares and votes in Abliva AB (publ)

Abliva
Press release26.08.2024 klo 09.46

BioStock: Abliva's CEO - We are the leading programme in mitochondrial disease

Abliva
Regulatory press release22.08.2024 klo 09.30

Abliva AB Interim Report January – June 2024

Abliva
Press release24.07.2024 klo 12.57

Abliva's CEO to BioStock: "One step closer to a marketed medicine"

Abliva
Regulatory press release19.07.2024 klo 09.30

Positive interim analysis in Abliva's FALCON study triggers convertible loan conversion

Abliva
Regulatory press release18.07.2024 klo 23.22

Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease

Abliva
Regulatory press release31.05.2024 klo 09.30

Amended number of shares and votes in Abliva AB (publ)

Abliva